Skip to main content

17.05.2024 | Original Communication

Neuroimaging assessment of facility-bound severely-affected MS reveals the critical role of cortical gray matter pathology: results from the CASA–MS case-controlled study

verfasst von: Robert Zivadinov, Dejan Jakimovski, Alex Burnham, Jens Kuhle, Zachary Weinstock, Taylor R. Wicks, Murali Ramanathan, Tommaso Sciortino, Mark Ostrem, Christopher Suchan, Michael G. Dwyer, Jessica Reilly, Niels Bergsland, Ferdinand Schweser, Cheryl Kennedy, David Young-Hong, Svetlana Eckert, David Hojnacki, Ralph H. B. Benedict, Bianca Weinstock-Guttman

Erschienen in: Journal of Neurology

Einloggen, um Zugang zu erhalten

Abstract

Background

A subgroup of people with multiple sclerosis (pwMS) will develop severe disability. The pathophysiology underlying severe MS is unknown. The comprehensive assessment of severely affected MS (CASA–MS) was a case-controlled study that compared severely disabled in skilled nursing (SD/SN) (EDSS ≥ 7.0) to less-disabled (EDSS 3.0–6.5) community dwelling (CD) progressive pwMS, matched on age-, sex- and disease-duration (DDM).

Objectives

To identify neuroimaging and molecular biomarker characteristics that distinguish SD/SN from DDM–CD progressive pwMS.

Methods

This study was carried at SN facility and at a tertiary MS center. The study collected clinical, molecular (serum neurofilament light chain, sNfL and glial acidic fibrillary protein, sGFAP) and MRI quantitative lesion-, brain volume-, and tissue integrity-derived measures. Statistical analyses were controlled for multiple comparisons.

Results

42 SD/SN and 42 DDM–CD were enrolled. SD/SN pwMS showed significantly lower cortical volume (CV) (p < 0.001, d = 1.375) and thalamic volume (p < 0.001, d = 0.972) compared to DDM–CD pwMS. In a logistic stepwise regression model, the SD/SN pwMS were best differentiated from the DDM–CD pwMS by lower CV (p < 0.001) as the only significant predictor, with the accuracy of 82.3%. No significant differences between the two groups were observed for medulla oblongata volume, a proxy for spinal cord atrophy and white matter lesion burden, while there was a statistical trend for numerically higher sGFAP in SD/SN pwMS.

Conclusions

The CASA–MS study showed significantly more gray matter atrophy in severe compared to less-severe progressive MS.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Arrambide G et al (2020) Aggressive multiple sclerosis (2): treatment. Mult Scler 26:1352458520924595PubMedCrossRef Arrambide G et al (2020) Aggressive multiple sclerosis (2): treatment. Mult Scler 26:1352458520924595PubMedCrossRef
2.
Zurück zum Zitat Barnett M et al (2021) Brain atrophy and lesion burden are associated with disability progression in a multiple sclerosis real-world dataset using only T2-FLAIR: the NeuroSTREAM MSBase study. Neuroimage Clin 32:102802PubMedPubMedCentralCrossRef Barnett M et al (2021) Brain atrophy and lesion burden are associated with disability progression in a multiple sclerosis real-world dataset using only T2-FLAIR: the NeuroSTREAM MSBase study. Neuroimage Clin 32:102802PubMedPubMedCentralCrossRef
3.
Zurück zum Zitat Benedict RH, Zivadinov R (2011) Risk factors for and management of cognitive dysfunction in multiple sclerosis. Nat Rev Neurol 7:332–342PubMedCrossRef Benedict RH, Zivadinov R (2011) Risk factors for and management of cognitive dysfunction in multiple sclerosis. Nat Rev Neurol 7:332–342PubMedCrossRef
4.
Zurück zum Zitat Benkert P et al (2022) Serum neurofilament light chain for individual prognostication of disease activity in people with multiple sclerosis: a retrospective modelling and validation study. Lancet Neurol 21:246–257PubMedCrossRef Benkert P et al (2022) Serum neurofilament light chain for individual prognostication of disease activity in people with multiple sclerosis: a retrospective modelling and validation study. Lancet Neurol 21:246–257PubMedCrossRef
5.
Zurück zum Zitat Benkert P et al. (2023) Serum glial fibrillary acidic protein (GFAP) is a longitudinal indicator of disease progression in MS while neurofilament light chain (NfL) associates with therapy response in patients under B cell depleting therapy. In: MSMilan. Vol., ed.^eds., Milan, Italy Benkert P et al. (2023) Serum glial fibrillary acidic protein (GFAP) is a longitudinal indicator of disease progression in MS while neurofilament light chain (NfL) associates with therapy response in patients under B cell depleting therapy. In: MSMilan. Vol., ed.^eds., Milan, Italy
6.
Zurück zum Zitat Calabrese M, Filippi M, Gallo P (2010) Cortical lesions in multiple sclerosis. Nat Rev Neurol 6:438–444PubMedCrossRef Calabrese M, Filippi M, Gallo P (2010) Cortical lesions in multiple sclerosis. Nat Rev Neurol 6:438–444PubMedCrossRef
7.
Zurück zum Zitat Dwyer MG et al (2017) Neurological software tool for reliable atrophy measurement (NeuroSTREAM) of the lateral ventricles on clinical-quality T2-FLAIR MRI scans in multiple sclerosis. Neuroimage Clin 15:769–779PubMedPubMedCentralCrossRef Dwyer MG et al (2017) Neurological software tool for reliable atrophy measurement (NeuroSTREAM) of the lateral ventricles on clinical-quality T2-FLAIR MRI scans in multiple sclerosis. Neuroimage Clin 15:769–779PubMedPubMedCentralCrossRef
8.
Zurück zum Zitat Dwyer MG et al (2018) Atrophied brain lesion volume: a new imaging biomarker in multiple sclerosis. J Neuroimaging 28:490–495PubMedCrossRef Dwyer MG et al (2018) Atrophied brain lesion volume: a new imaging biomarker in multiple sclerosis. J Neuroimaging 28:490–495PubMedCrossRef
10.
Zurück zum Zitat Edmonds P et al (2007) Loss and change: experiences of people severely affected by multiple sclerosis. Palliat Med 21:101–107PubMedCrossRef Edmonds P et al (2007) Loss and change: experiences of people severely affected by multiple sclerosis. Palliat Med 21:101–107PubMedCrossRef
11.
Zurück zum Zitat Favaretto A et al (2016) MRI-detectable cortical lesions in the cerebellum and their clinical relevance in multiple sclerosis. Mult Scler 22:494–501PubMedCrossRef Favaretto A et al (2016) MRI-detectable cortical lesions in the cerebellum and their clinical relevance in multiple sclerosis. Mult Scler 22:494–501PubMedCrossRef
12.
Zurück zum Zitat Fuchs TA et al (2018) Impact of focal white matter damage on localized subcortical gray matter atrophy in multiple sclerosis: a 5-year study. AJNR Am J Neuroradiol 39:1480–1486PubMedPubMedCentral Fuchs TA et al (2018) Impact of focal white matter damage on localized subcortical gray matter atrophy in multiple sclerosis: a 5-year study. AJNR Am J Neuroradiol 39:1480–1486PubMedPubMedCentral
13.
Zurück zum Zitat Fuchs TA et al (2018) White matter tract network disruption explains reduced conscientiousness in multiple sclerosis. Hum Brain Mapp 39:3682–3690PubMedPubMedCentralCrossRef Fuchs TA et al (2018) White matter tract network disruption explains reduced conscientiousness in multiple sclerosis. Hum Brain Mapp 39:3682–3690PubMedPubMedCentralCrossRef
14.
Zurück zum Zitat Fuchs TA et al (2021) Quantifying disease pathology and predicting disease progression in multiple sclerosis with only clinical routine T2-FLAIR MRI. Neuroimage Clin 31:102705PubMedPubMedCentralCrossRef Fuchs TA et al (2021) Quantifying disease pathology and predicting disease progression in multiple sclerosis with only clinical routine T2-FLAIR MRI. Neuroimage Clin 31:102705PubMedPubMedCentralCrossRef
15.
Zurück zum Zitat Gass A et al (2015) MRI monitoring of pathological changes in the spinal cord in patients with multiple sclerosis. Lancet Neurol 14:443–454PubMedCrossRef Gass A et al (2015) MRI monitoring of pathological changes in the spinal cord in patients with multiple sclerosis. Lancet Neurol 14:443–454PubMedCrossRef
16.
Zurück zum Zitat Gelineau-Morel R et al (2011) The effect of hypointense white matter lesions on automated gray matter segmentation in multiple sclerosis. Hum Brain Mapp 33:2802–2814PubMedPubMedCentralCrossRef Gelineau-Morel R et al (2011) The effect of hypointense white matter lesions on automated gray matter segmentation in multiple sclerosis. Hum Brain Mapp 33:2802–2814PubMedPubMedCentralCrossRef
17.
Zurück zum Zitat Genovese AV et al (2019) Atrophied brain T2 lesion volume at MRI Is associated with disability progression and conversion to secondary progressive multiple sclerosis. Radiology 293:424–433PubMedCrossRef Genovese AV et al (2019) Atrophied brain T2 lesion volume at MRI Is associated with disability progression and conversion to secondary progressive multiple sclerosis. Radiology 293:424–433PubMedCrossRef
18.
Zurück zum Zitat Harrison DM et al (2015) Thalamic lesions in multiple sclerosis by 7T MRI: clinical implications and relationship to cortical pathology. Mult Scler 21:1139–1150PubMedPubMedCentralCrossRef Harrison DM et al (2015) Thalamic lesions in multiple sclerosis by 7T MRI: clinical implications and relationship to cortical pathology. Mult Scler 21:1139–1150PubMedPubMedCentralCrossRef
19.
Zurück zum Zitat Higginson IJ et al (2006) Symptom prevalence and severity in people severely affected by multiple sclerosis. J Palliat Care 22:158–165PubMedCrossRef Higginson IJ et al (2006) Symptom prevalence and severity in people severely affected by multiple sclerosis. J Palliat Care 22:158–165PubMedCrossRef
20.
Zurück zum Zitat Iacobaeus E et al (2020) Aggressive multiple sclerosis (1): towards a definition of the phenotype. Mult Scler 26:1352458520925369PubMedCrossRef Iacobaeus E et al (2020) Aggressive multiple sclerosis (1): towards a definition of the phenotype. Mult Scler 26:1352458520925369PubMedCrossRef
21.
Zurück zum Zitat Jakimovski D et al (2019) Serum neurofilament light chain levels associations with gray matter pathology: a 5-year longitudinal study. Ann Clin Transl Neurol 6:1757–1770PubMedPubMedCentralCrossRef Jakimovski D et al (2019) Serum neurofilament light chain levels associations with gray matter pathology: a 5-year longitudinal study. Ann Clin Transl Neurol 6:1757–1770PubMedPubMedCentralCrossRef
22.
Zurück zum Zitat Jakimovski D et al (2022) Multisite MRI reproducibility of lateral ventricular volume using the NAIMS cooperative pilot dataset. J Neuroimaging 32:910–919PubMedPubMedCentralCrossRef Jakimovski D et al (2022) Multisite MRI reproducibility of lateral ventricular volume using the NAIMS cooperative pilot dataset. J Neuroimaging 32:910–919PubMedPubMedCentralCrossRef
23.
24.
25.
Zurück zum Zitat Kopke S et al (2019) Patient and caregiver involvement in the formulation of guideline questions: findings from the European Academy of Neurology guideline on palliative care of people with severe multiple sclerosis. Eur J Neurol 26:41–50PubMedCrossRef Kopke S et al (2019) Patient and caregiver involvement in the formulation of guideline questions: findings from the European Academy of Neurology guideline on palliative care of people with severe multiple sclerosis. Eur J Neurol 26:41–50PubMedCrossRef
26.
Zurück zum Zitat Kuceyeski A et al (2013) The Network Modification (NeMo) Tool: elucidating the effect of white matter integrity changes on cortical and subcortical structural connectivity. Brain Connect 3:451–463PubMedPubMedCentralCrossRef Kuceyeski A et al (2013) The Network Modification (NeMo) Tool: elucidating the effect of white matter integrity changes on cortical and subcortical structural connectivity. Brain Connect 3:451–463PubMedPubMedCentralCrossRef
27.
Zurück zum Zitat Kumpfel T et al (2007) Palliative care in patients with severe multiple sclerosis: two case reports and a survey among German MS neurologists. Palliat Med 21:109–114PubMedCrossRef Kumpfel T et al (2007) Palliative care in patients with severe multiple sclerosis: two case reports and a survey among German MS neurologists. Palliat Med 21:109–114PubMedCrossRef
28.
Zurück zum Zitat Lie IA et al (2022) Relationship between white matter lesions and gray matter atrophy in multiple sclerosis: a systematic review. Neurology 98:e1562–e1573PubMedPubMedCentralCrossRef Lie IA et al (2022) Relationship between white matter lesions and gray matter atrophy in multiple sclerosis: a systematic review. Neurology 98:e1562–e1573PubMedPubMedCentralCrossRef
29.
Zurück zum Zitat Liptak Z et al (2008) Medulla oblongata volume: a biomarker of spinal cord damage and disability in multiple sclerosis. AJNR Am J Neuroradiol 29:1465–1470PubMedPubMedCentralCrossRef Liptak Z et al (2008) Medulla oblongata volume: a biomarker of spinal cord damage and disability in multiple sclerosis. AJNR Am J Neuroradiol 29:1465–1470PubMedPubMedCentralCrossRef
31.
Zurück zum Zitat Mainero C, Treaba CA, Barbuti E (2023) Imaging cortical lesions in multiple sclerosis. Curr Opin Neurol 36:222–228PubMedCrossRef Mainero C, Treaba CA, Barbuti E (2023) Imaging cortical lesions in multiple sclerosis. Curr Opin Neurol 36:222–228PubMedCrossRef
32.
Zurück zum Zitat Meier S et al (2023) Serum glial fibrillary acidic protein compared with neurofilament light chain as a biomarker for disease progression in multiple sclerosis. JAMA Neurol 80:287–297PubMedPubMedCentralCrossRef Meier S et al (2023) Serum glial fibrillary acidic protein compared with neurofilament light chain as a biomarker for disease progression in multiple sclerosis. JAMA Neurol 80:287–297PubMedPubMedCentralCrossRef
33.
Zurück zum Zitat Muller A et al (2023) Development of a long-term cross-sectoral case and care management manual for patients with severe multiple sclerosis and their caregivers. Prof Case Manag 28:183–193PubMedCrossRef Muller A et al (2023) Development of a long-term cross-sectoral case and care management manual for patients with severe multiple sclerosis and their caregivers. Prof Case Manag 28:183–193PubMedCrossRef
35.
Zurück zum Zitat Smith SM et al (2002) Accurate, robust, and automated longitudinal and cross-sectional brain change analysis. Neuroimage 17:479–489PubMedCrossRef Smith SM et al (2002) Accurate, robust, and automated longitudinal and cross-sectional brain change analysis. Neuroimage 17:479–489PubMedCrossRef
36.
Zurück zum Zitat Thompson AJ et al (2017) Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. Lancet Neurol 17(2):162–173PubMedCrossRef Thompson AJ et al (2017) Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. Lancet Neurol 17(2):162–173PubMedCrossRef
37.
Zurück zum Zitat Trapp BD et al (2018) Cortical neuronal densities and cerebral white matter demyelination in multiple sclerosis: a retrospective study. Lancet Neurol 17:870–884PubMedPubMedCentralCrossRef Trapp BD et al (2018) Cortical neuronal densities and cerebral white matter demyelination in multiple sclerosis: a retrospective study. Lancet Neurol 17:870–884PubMedPubMedCentralCrossRef
38.
Zurück zum Zitat Vaughn CB et al (2019) Epidemiology and treatment of multiple sclerosis in elderly populations. Nat Rev Neurol 15:329–342PubMedCrossRef Vaughn CB et al (2019) Epidemiology and treatment of multiple sclerosis in elderly populations. Nat Rev Neurol 15:329–342PubMedCrossRef
39.
Zurück zum Zitat Wattjes MP et al (2021) 2021 MAGNIMS-CMSC-NAIMS consensus recommendations on the use of MRI in patients with multiple sclerosis. Lancet Neurol 20:653–670PubMedCrossRef Wattjes MP et al (2021) 2021 MAGNIMS-CMSC-NAIMS consensus recommendations on the use of MRI in patients with multiple sclerosis. Lancet Neurol 20:653–670PubMedCrossRef
40.
Zurück zum Zitat Younus Z et al (2017) Fatigue and mood states in nursing home and nonambulatory home-based patients with multiple sclerosis. Int J MS Care 19:297–302PubMedPubMedCentralCrossRef Younus Z et al (2017) Fatigue and mood states in nursing home and nonambulatory home-based patients with multiple sclerosis. Int J MS Care 19:297–302PubMedPubMedCentralCrossRef
41.
Zurück zum Zitat Zivadinov R et al (2012) Abnormal subcortical deep-gray matter susceptibility-weighted imaging filtered phase measurements in patients with multiple sclerosis: a case-control study. Neuroimage 59:331–339PubMedCrossRef Zivadinov R et al (2012) Abnormal subcortical deep-gray matter susceptibility-weighted imaging filtered phase measurements in patients with multiple sclerosis: a case-control study. Neuroimage 59:331–339PubMedCrossRef
42.
Zurück zum Zitat Zivadinov R et al (2016) Clinical relevance of brain atrophy assessment in multiple sclerosis. Implications for its use in a clinical routine. Expert Rev Neurother 16:1–17CrossRef Zivadinov R et al (2016) Clinical relevance of brain atrophy assessment in multiple sclerosis. Implications for its use in a clinical routine. Expert Rev Neurother 16:1–17CrossRef
43.
Zurück zum Zitat Zivadinov R et al (2018) Feasibility of brain atrophy measurement in clinical routine without prior standardization of the MRI protocol: results from MS-MRIUS, a longitudinal observational, multicenter real-world outcome study in patients with relapsing-remitting MS. AJNR Am J Neuroradiol 39:289–295PubMedPubMedCentralCrossRef Zivadinov R et al (2018) Feasibility of brain atrophy measurement in clinical routine without prior standardization of the MRI protocol: results from MS-MRIUS, a longitudinal observational, multicenter real-world outcome study in patients with relapsing-remitting MS. AJNR Am J Neuroradiol 39:289–295PubMedPubMedCentralCrossRef
44.
Zurück zum Zitat Zivadinov R et al (2022) Thalamic atrophy measured by artificial intelligence in a multicentre clinical routine real-word study is associated with disability progression. J Neurol Neurosurg Psychiatry 93:1128–1136CrossRef Zivadinov R et al (2022) Thalamic atrophy measured by artificial intelligence in a multicentre clinical routine real-word study is associated with disability progression. J Neurol Neurosurg Psychiatry 93:1128–1136CrossRef
Metadaten
Titel
Neuroimaging assessment of facility-bound severely-affected MS reveals the critical role of cortical gray matter pathology: results from the CASA–MS case-controlled study
verfasst von
Robert Zivadinov
Dejan Jakimovski
Alex Burnham
Jens Kuhle
Zachary Weinstock
Taylor R. Wicks
Murali Ramanathan
Tommaso Sciortino
Mark Ostrem
Christopher Suchan
Michael G. Dwyer
Jessica Reilly
Niels Bergsland
Ferdinand Schweser
Cheryl Kennedy
David Young-Hong
Svetlana Eckert
David Hojnacki
Ralph H. B. Benedict
Bianca Weinstock-Guttman
Publikationsdatum
17.05.2024
Verlag
Springer Berlin Heidelberg
Erschienen in
Journal of Neurology
Print ISSN: 0340-5354
Elektronische ISSN: 1432-1459
DOI
https://doi.org/10.1007/s00415-024-12420-2

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Nicht Creutzfeldt Jakob, sondern Abführtee-Vergiftung

29.05.2024 Hyponatriämie Nachrichten

Eine ältere Frau trinkt regelmäßig Sennesblättertee gegen ihre Verstopfung. Der scheint plötzlich gut zu wirken. Auf Durchfall und Erbrechen folgt allerdings eine Hyponatriämie. Nach deren Korrektur kommt es plötzlich zu progredienten Kognitions- und Verhaltensstörungen.

Schutz der Synapsen bei Alzheimer

29.05.2024 Morbus Alzheimer Nachrichten

Mit einem Neurotrophin-Rezeptor-Modulator lässt sich möglicherweise eine bestehende Alzheimerdemenz etwas abschwächen: Erste Phase-2-Daten deuten auf einen verbesserten Synapsenschutz.

Sozialer Aufstieg verringert Demenzgefahr

24.05.2024 Demenz Nachrichten

Ein hohes soziales Niveau ist mit die beste Versicherung gegen eine Demenz. Noch geringer ist das Demenzrisiko für Menschen, die sozial aufsteigen: Sie gewinnen fast zwei demenzfreie Lebensjahre. Umgekehrt steigt die Demenzgefahr beim sozialen Abstieg.

Hirnblutung unter DOAK und VKA ähnlich bedrohlich

17.05.2024 Direkte orale Antikoagulanzien Nachrichten

Kommt es zu einer nichttraumatischen Hirnblutung, spielt es keine große Rolle, ob die Betroffenen zuvor direkt wirksame orale Antikoagulanzien oder Marcumar bekommen haben: Die Prognose ist ähnlich schlecht.

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.